Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

876498.pdf (5.39 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2024-09-30

Llicència de publicació

cc-by (c) Roya Mohammadi-Meyabadi et al., 2024
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/217865

Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/pharmaceutics16101287

Resum

Background: Baricitinib, commonly used for autoimmune diseases, is typically administered orally, which can lead to systemic adverse effects. A topical formulation could potentially offer localized therapeutic effects while minimizing these side effects. Objectives: This study focuses on developing a lipid-based topical formulation of baricitinib (BCT-OS) for treating psoriasis. Methods: The optimized formulation was then assessed for physical, chemical, and biopharmaceutical characterization. Furthermore, the anti-inflammatory efficacy of the formulation was tested in a model of psoriasis induced by imiquimod in mice, and its tolerance was determined by the evaluation of biomechanical skin properties and an inflammation test model induced by xylol in mice. Results: BCT-OS presented appropriate characteristics for skin administration in terms of pH, rheology, extensibility, and stability. The formulation also demonstrated a notable reduction in skin inflammation in the mouse model, and high tolerability without affecting the skin integrity. Conclusions: BCT-OS shows promise as an alternative treatment for psoriasis, offering localized therapeutic benefits with a potentially improved safety profile compared to systemic administration.

Matèries

Psoriasi, Malalties de la pell, Lípids

Matèries (anglès)

Psoriasis, Skin diseases, Lipids

Citació

Col·leccions

Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Citació

MOHAMMADI-MEYABADI, Roya, et al. Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis. Pharmaceutics. 2024. Vol. 16, num. 10. ISSN 1999-4923. [consulted: 4 of August of 2026]. Available at: https://hdl.handle.net/2445/217865

Exportar metadades

JSON - METS

Compartir registre